FDA As Drug Developer: Voucher For AstraZeneca, Orphan Indication For Wellstat
Executive Summary
Hoping to head off shortage of another product, FDA’s intervention gives both Wellstat and AstraZeneca quicker paths to market for their drugs in what could almost be a regulatory fairytale.
You may also be interested in...
How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say
Companies’ decision to purchase and redeem BioMarin’s priority review voucher for their PCSK9 inhibitor alirocumab sets the first public benchmark for a voucher’s value and shows the potential advantages to be gained for sponsors in a race to market.
Jazz Hits High Note With Updated Zanidatamab Data In Biliary Tract Cancer At ASCO
The company said it is in talks with the US FDA for an accelerated approval filing of the HER2-directed bispecific antibody, which showed better ORR and PFS than the standard of care.
US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month
Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.